Comparison of rizatriptan 5 mg and 10 mg tablets and sumatriptan 25 mg and 50 mg tablets

Cephalalgia

Volumn 24, Issue 7, 2004, Pages 540-546

  Kolodny, A ^a   Polis, A ^a   Battisti, W P ^a   Johnson Pratt, L ^a   Skobieranda, F ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Headache; Migraine; Pain relief; Rizatriptan; Sumatriptan

Indexed keywords

RIZATRIPTAN; SUMATRIPTAN;

ADULT; ANALGESIA; ARTICLE; ASTHENIA; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; FLUSHING; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; NAUSEA; PAIN ASSESSMENT; PARESTHESIA; PHYSICAL DISABILITY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE; TABLET FORMULATION; THORAX PAIN; XEROSTOMIA;

ADULT; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIGRAINE DISORDERS; SUMATRIPTAN; TABLETS; TRIAZOLES; TRYPTAMINES;

EID: 4644312603     PISSN: 03331024     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-2982.2004.00707.x     Document Type: Article

References (13)

1. Goldstein J, Ryan R, Jiang K, Getson A, Norman B, Block G et al. Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 mg and 50 mg in migraine. Headache 1998; 38:737-47.
2. Lines CR, McCarroll KA, Visser WH. Rizatriptan: pharmacological differences from sumatriptan and clinical results. Curr Med Res Opin 2001; 17 (Suppl. 1):54-8.
3. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT(1B/ID) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001; 358:1668-75.
4. Adelman JU, Lipton RB, Ferrari MD, Diener HC, McCarroll KA, Vandormael K et al. Comparison of rizatriptan and other triptans on stringent measures of efficacy. Neurology 2001; 57:1377-83.
5. Lipton RB, Pascual J, Goadsby PJ, Massiou H, McCarroll KA, Vandormael K et al. Effect of rizatriptan and other triptans on the nausea symptom of migraine: a post hoc analysis. Headache 2001; 41:754-63.
6. Bussone G, D'Amico D, McCarroll KA, Gerth W, Lines CR. Restoring migraine sufferers' ability to function normally: a comparison of rizatriptan and other triptans in randomized trials. Eur Neurol 2002; 48:172-7.
7. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988; 8:1-98.
8. Allen C, Jiang K, Malbecq W, Goadsby PJ. Time-to-event analysis, or who gets better sooner? An emerging concept in headache study methodology. Cephalalgia 1999; 19:552-6.
9. Tfelt-Hansen P, Teall J, Rodriguez R, Giacovazzo M, Paz J, Malbecq W et al. Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Headache 1998; 38:748-55.
10. 1D agonist. Br J Clin Pharmacol 1997; 43:49-54.
11. Fowler PA, Lacey LF, Thomas M, Keene ON, Tanner RJ, Baber NS. The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. Eur Neurol 1991; 31:291-4.
12. Ploskser GL, McTavish D. Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs 1994; 47:622-51.
13. Pfaffenrath V, Cunin G, Sjonell G, Prendergast S. Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine; defining the optimum doses of oral sumatriptan. Headache 1998; 38:184-90.